News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Esperion Therapeutics, Inc. (ESPR) Announces The Appointment Of Gilbert S. Omenn, M.D., Ph.D. To Board Of Directors


6/26/2014 7:33:55 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced the appointment of Gilbert S. Omenn, M.D., Ph.D. as a Class II Director, with a term of office expiring in 2015 at the annual meeting of stockholders.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES